VITAL - Individualising Therapy for Neovascular AMD With Aflibercept
Status:
Completed
Trial end date:
2018-01-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess a new treatment pattern for aflibercept. The aim is to
achieve and maintain the best benefit of visual function and avoid unnecessary hospital
visits.
The hypothesis to be tested is whether intravitreous aflibercept given in an 8 week cycle of
treatment in year 1 and a capped treat and extend treatment paradigm in year 2 can lead to
improved vision and reading speed in eyes with active wet AMD over 2 years while reducing
hospital visits.